Analysis of Routing Worm Infection Rates on an IPV4 Network

Malicious logic, specifically worms, has caused monetary expenditure problems to network users in the past. Worms, like Slammer and Code Red, have infected thousands of systems and brought the Internet to a standstill. This research examines the ability of the original Slammer worm, the Slammer based routing worm proposed by Zou et al, and a new Single Slash Eight (SSE) routing worm proposed by this research to infect vulnerable systems within a given address space. This research investigates the Slammer worm\u27s ability to generate a uniform random IP addresses in a given address space. Finally, a comparison of the speed increase from computing systems available today versus those in use during the original Slammer release is performed. This research finds that the both the Slammer based routing worm and the SSE routing worm are faster than the original Slammer. The random number generator of the original Slammer worm does generate a statistically uniform distribution of addresses within the range under test. Further, this research shows that despite the previous research into the speed of worm propagation, there is a large void in testing worms on the systems available today that need to be investigated. The speed of the computing systems that the worms operated on in the past were more than three times slower than today\u27s systems. As the speed of computer systems continue to grow, the speed of worm propagation should increase with it as their scan rates directly relate to their infection rate. As such, the immunity of the future IPv6 network, from scanning worms may need to be reexamined

AccessRI

AccessRI, a studio team comprised of ten graduate students in the Department of Urban Affairs and Planning at Hunter College, was commissioned by New York State Senator José M. Serrano to identify and provide strategies to address residents’ concerns regarding the quality of life on Roosevelt Island. Roosevelt Island, located between Manhattan and Queens in the East River, is an exceptional place within the varied fabric of New York City. The island provides its residents with an existence apart from the typical hassles associated with urban life, yet its proximity to the rest of the city allows residents to partake in countless amenities. Not only does the island possess a unique geographic location, but its history as a master-planned community has helped to create its distinct character, while simultaneously creating many challenges. Roosevelt Island was virtually abandoned after decades of service as a place for New York’s sick and infirmed. The city, under the Lindsay administration, embarked on an ambitious redevelopment plan. The master plan designed by architects Philip Johnson and John Burgee in 1969, utilized the island’s exceptional views and established a framework for an idealized, “auto-free,” mixed-use development. The development scheme included low and moderate-income housing, a parking garage, the preservation of six historic structures, abundant public spaces and a commercial corridor. The original master plan successfully established a distinctive community that enjoys some of the finest views and greatest amounts of open space that the city has to offer. Yet despite these advantages, the current residents of the island are struggling with a myriad of issues that range from problems caused by aging and neglected infrastructure to demographic and social changes resulting from an influx of residents moving into newly built or renovated residential developments. These concerns are coupled with residents’ perceptions of inadequate governance, that result in the feeling that their concerns are ignored and will never be addressed. Through initial investigation, AccessRI found that the best way to assist residents in improving their quality of life would be to improve access to the facilities and services necessary for well-being

Goals and regulations of religiosity: A motivational analysis

The fields of religious and motivation psychology have quite independently developed their own conceptualizations and research agendas. Few schol-ars, however, have examined issues that are at the intersection of both fields and, if so, most researchers in the psychology of religion did not make use of existing general motivational frameworks to enrich their understanding of the motivational dynamics for religious behaviors. The aim of the present chapter is to indicate how self-determination theory (Ryan & Deci, (2000a) American Psychologist, 55, 68–78) might help to further refine Allport’s classical distinction between intrinsic and extrinsic religious orientation. Specifically, it is argued that the reasons or reg-ulations for religious behavior (initially, intrinsic vs. extrinsic; later, au-tonomous vs. controlled) and the goals of religious behavior (intrinsic vs. extrinsic), as they are defined within self-determination theory, are not distinguished within Allport’s and other researchers ’ frameworks. Both conceptual dimensions might better be disentangled, so that their inde-pendent effects could be studied. 1

Trapping \u3ci\u3ePhyllophaga \u3c/i\u3espp. (Coleoptera: Scarabaeidae: Melolonthinae) in the United States and Canada using sex attractants.

The sex pheromone of the scarab beetle, Phyllophaga anxia, is a blend of the methyl esters of two amino acids, L-valine and L-isoleucine. A field trapping study was conducted, deploying different blends of the two compounds at 59 locations in the United States and Canada. More than 57,000 males of 61 Phyllophaga species (Coleoptera: Scarabaeidae: Melolonthinae) were captured and identified. Three major findings included: (1) widespread use of the two compounds [of the 147 Phyllophaga (sensu stricto) species found in the United States and Canada, males of nearly 40% were captured]; (2) in most species intraspecific male response to the pheromone blends was stable between years and over geography; and (3) an unusual pheromone polymorphism was described from P. anxia. Populations at some locations were captured with L-valine methyl ester alone, whereas populations at other locations were captured with L-isoleucine methyl ester alone. At additional locations, the L-valine methyl ester-responding populations and the L-isoleucine methyl ester-responding populations were both present, producing a bimodal capture curve. In southeastern Massachusetts and in Rhode Island, in the United States, P. anxia males were captured with blends of L-valine methyl ester and L-isoleucine methyl ester

Personality traits and mental disorders

Peer reviewe

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial

Background Cough can be a debilitating symptom of idiopathic pulmonary fibrosis (IPF) and is difficult to treat. PA101 is a novel formulation of sodium cromoglicate delivered via a high-efficiency eFlow nebuliser that achieves significantly higher drug deposition in the lung compared with the existing formulations. We aimed to test the efficacy and safety of inhaled PA101 in patients with IPF and chronic cough and, to explore the antitussive mechanism of PA101, patients with chronic idiopathic cough (CIC) were also studied. Methods This pilot, proof-of-concept study consisted of a randomised, double-blind, placebo-controlled trial in patients with IPF and chronic cough and a parallel study of similar design in patients with CIC. Participants with IPF and chronic cough recruited from seven centres in the UK and the Netherlands were randomly assigned (1:1, using a computer-generated randomisation schedule) by site staff to receive PA101 (40 mg) or matching placebo three times a day via oral inhalation for 2 weeks, followed by a 2 week washout, and then crossed over to the other arm. Study participants, investigators, study staff, and the sponsor were masked to group assignment until all participants had completed the study. The primary efficacy endpoint was change from baseline in objective daytime cough frequency (from 24 h acoustic recording, Leicester Cough Monitor). The primary efficacy analysis included all participants who received at least one dose of study drug and had at least one post-baseline efficacy measurement. Safety analysis included all those who took at least one dose of study drug. In the second cohort, participants with CIC were randomly assigned in a study across four centres with similar design and endpoints. The study was registered with ClinicalTrials.gov (NCT02412020) and the EU Clinical Trials Register (EudraCT Number 2014-004025-40) and both cohorts are closed to new participants. Findings Between Feb 13, 2015, and Feb 2, 2016, 24 participants with IPF were randomly assigned to treatment groups. 28 participants with CIC were enrolled during the same period and 27 received study treatment. In patients with IPF, PA101 reduced daytime cough frequency by 31·1% at day 14 compared with placebo; daytime cough frequency decreased from a mean 55 (SD 55) coughs per h at baseline to 39 (29) coughs per h at day 14 following treatment with PA101, versus 51 (37) coughs per h at baseline to 52 (40) cough per h following placebo treatment (ratio of least-squares [LS] means 0·67, 95% CI 0·48–0·94, p=0·0241). By contrast, no treatment benefit for PA101 was observed in the CIC cohort; mean reduction of daytime cough frequency at day 14 for PA101 adjusted for placebo was 6·2% (ratio of LS means 1·27, 0·78–2·06, p=0·31). PA101 was well tolerated in both cohorts. The incidence of adverse events was similar between PA101 and placebo treatments, most adverse events were mild in severity, and no severe adverse events or serious adverse events were reported. Interpretation This study suggests that the mechanism of cough in IPF might be disease specific. Inhaled PA101 could be a treatment option for chronic cough in patients with IPF and warrants further investigation

Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

Background The risk factors for recovery from COVID-19 dyspnoea are poorly understood. We investigated determinants of recovery from dyspnoea in adults with COVID-19 and compared these to determinants of recovery from non-COVID-19 dyspnoea. Methods We used data from two prospective cohort studies: PHOSP-COVID (patients hospitalised between March 2020 and April 2021 with COVID-19) and COVIDENCE UK (community cohort studied over the same time period). PHOSP-COVID data were collected during hospitalisation and at 5-month and 1-year follow-up visits. COVIDENCE UK data were obtained through baseline and monthly online questionnaires. Dyspnoea was measured in both cohorts with the Medical Research Council Dyspnoea Scale. We used multivariable logistic regression to identify determinants associated with a reduction in dyspnoea between 5-month and 1-year follow-up. Findings We included 990 PHOSP-COVID and 3309 COVIDENCE UK participants. We observed higher odds of improvement between 5-month and 1-year follow-up among PHOSP-COVID participants who were younger (odds ratio 1.02 per year, 95% CI 1.01–1.03), male (1.54, 1.16–2.04), neither obese nor severely obese (1.82, 1.06–3.13 and 4.19, 2.14–8.19, respectively), had no pre-existing anxiety or depression (1.56, 1.09–2.22) or cardiovascular disease (1.33, 1.00–1.79), and shorter hospital admission (1.01 per day, 1.00–1.02). Similar associations were found in those recovering from non-COVID-19 dyspnoea, excluding age (and length of hospital admission). Interpretation Factors associated with dyspnoea recovery at 1-year post-discharge among patients hospitalised with COVID-19 were similar to those among community controls without COVID-19. Funding PHOSP-COVID is supported by a grant from the MRC-UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research (NIHR) rapid response panel to tackle COVID-19. The views expressed in the publication are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health and Social Care. COVIDENCE UK is supported by the UK Research and Innovation, the National Institute for Health Research, and Barts Charity. The views expressed are those of the authors and not necessarily those of the funders

Perceived spirituality, mindfulness and quality of life in psychiatric patients

There is some evidence of the relationship between spirituality and quality of life, but there are few bibliographic references on these constructs for patients suffering from mental illness; thus, this study was aimed at revealing the possible role of spiritual outlooks as a protective factor in these individuals. The sample consisted of 96 Portuguese psychiatric patients, selected from a psychiatric hospital and assessed based on parameters for quality of life, spirituality and mindfulness. The data support some theories about the nature of the spirituality. Spiritual beliefs are poorly correlated with the quality of life index, and there is a moderate association between these beliefs and some aspects of mindfulness. It is suggested that a spiritual outlook of psychiatric patients should be taken into account in psychological interventions